Compare
Baxter International Inc vs Solventum Corp vs ResMed Inc vs 3M Co
| Latest fiscal year | Baxter International Inc BAX | Solventum Corp SOLV | ResMed Inc RMD | 3M Co MMM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $11.24B | $8.32B | $5.65B | $24.95B |
| Revenue growth (YoY) | +5.7% | +0.9% | +9.9% | +1.5% |
| Gross margin | 30.1% | 53.5% | 61.1% | 39.9% (computed) |
| Operating margin | -2.7% | 26.2% | 33.4% | 18.6% |
| Net margin | -8.5% | 18.7% | 26.9% | 13.0% |
| Net income | -$957.00M | $1.56B | $1.52B | $3.25B |
| EPS (Diluted) | -$1.87 | $8.88 | $10.43 | $6.00 |
| Operating cash flow | $845.00M | $369.00M | $1.81B | $2.31B |
| Free cash flow | $332.00M | -$10.00M | $1.65B | $1.40B |
| Cash & equivalents | $1.97B | $878.00M | $1.47B | n/a |
| Total assets | $20.05B | $14.29B | $8.97B | $37.73B |
| Total liabilities | $13.95B | $9.24B | $2.38B | $32.99B |
| Shareholders' equity | $6.10B | $5.05B | $6.59B | $4.75B |
| Return on year-end equity | -15.7% | 30.8% | 23.1% | 68.5% |
| Shares outstanding | n/a | 173.49M | 144.24M | 530.28M |
Revenue, most recent five fiscal years
| Fiscal year | Baxter International Inc | Solventum Corp | ResMed Inc | 3M Co |
|---|---|---|---|---|
| Latest | $11.24B Ended 2025-12-31 | $8.32B Ended 2025-12-31 | $5.65B Ended 2026-06-30 | $24.95B Ended 2025-12-31 |
| 1 year earlier | $10.64B Ended 2024-12-31 | $8.25B Ended 2024-12-31 | $5.15B Ended 2025-06-30 | $24.57B Ended 2024-12-31 |
| 2 years earlier | $10.36B Ended 2023-12-31 | $8.20B Ended 2023-12-31 | $4.69B Ended 2024-06-30 | $24.61B Ended 2023-12-31 |
| 3 years earlier | $10.06B Ended 2022-12-31 | $8.13B Ended 2022-12-31 | $4.22B Ended 2023-06-30 | $26.16B Ended 2022-12-31 |
| 4 years earlier | $12.15B Ended 2021-12-31 | n/a | $3.58B Ended 2022-06-30 | $35.35B Ended 2021-12-31 |